Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Oncology · Hepatocellular Carcinoma

Life After Treatment: Surveillance and Survivorship

At a Glance

After hepatocellular carcinoma (HCC) treatment, lifelong monitoring is essential to catch potential recurrence early. Survivorship involves regular MRI or CT scans and AFP blood tests, managing underlying liver disease like cirrhosis, and monitoring for signs of liver decompensation.

Completing primary treatment for Hepatocellular Carcinoma (HCC) is a major milestone, but it also marks the beginning of a new phase: survivorship. Because the liver environment that produced the first tumor remains, diligent monitoring is the most powerful tool you have to ensure long-term health [1].

Understanding the Risks of Recurrence

Recurrence means the cancer has returned. Doctors generally divide this into two categories based on when it happens:

  • Early Recurrence (within 2 years): This is usually caused by tiny cells from the original tumor that were not visible during treatment [2]. It is more likely if the original tumor was large or had microvascular invasion [3].
  • Late Recurrence (after 2 years): This is typically a “new” cancer that develops because the underlying liver (often due to cirrhosis or MASLD) is still prone to forming tumors [2][4].

The most common site for recurrence is the liver itself, though it can occasionally spread to the lungs or bones [4][5].

Your Surveillance Roadmap

While every hospital has its own specific protocol, most surveillance schedules follow a similar evidence-based timeline [6][7]:

Time Period Frequency What to Expect
Years 1 & 2 Every 3 to 6 months High-intensity monitoring with MRI or CT and AFP blood tests to catch early recurrence [6][8].
Years 3 to 5 Every 6 months Continued imaging and blood work, as the risk shifts toward “late” recurrence [9].
Years 5+ Every 6 to 12 months Lifelong monitoring is usually required, especially if you have underlying cirrhosis [10].

Managing “Scanxiety”

It is completely normal to feel a spike in distress around the time of your follow-up appointments—a phenomenon often called scanxiety [11].

  • The Sensation: Knowing what to expect physically can help. During an MRI or CT scan, you may be given a contrast dye through an IV. This often causes a sudden, warm flush over your body and sometimes a metallic taste in your mouth. This is completely normal and passes quickly.
  • The Wait: The wait for results is often the most difficult period [12]. Ask your doctor if results can be released through a patient portal as soon as they are ready to minimize the waiting period [12]. Focus-based strategies and speaking with your care team can help lower anxiety levels [13][14].

Quality of Life and Long-Term Health

Survivorship is about more than just scans; it is about how you feel.

  • The Vital Role of Caregivers: Recovery, especially after major surgery or transplant, relies heavily on caregivers. They are often the first to notice subtle signs of complications, like the confusion associated with hepatic encephalopathy. Caregivers need support and open communication with the care team just as much as the patient does.
  • Liver Function: If you had a resection (surgery), your team will monitor you for signs of liver decompensation (when the remaining liver struggles to keep up) [15].
  • Immunosuppression: Transplant recipients must manage the long-term side effects of anti-rejection drugs, which can affect kidney function and increase the risk of other infections [16].
  • The “Second Chance”: Because late recurrence is linked to the health of your liver tissue, managing your “background” disease—such as treating Hepatitis C, controlling diabetes, or maintaining a healthy weight—is a proactive way to reduce your risk of a new cancer forming [4][17].

Regular exercise and a supportive community are also associated with better health-related quality of life (HRQoL) in the years following HCC treatment [18][19].

Common questions in this guide

What is the difference between early and late liver cancer recurrence?
Early recurrence usually happens within two years and is caused by microscopic cancer cells left behind after treatment. Late recurrence occurs after two years and is typically a new tumor that develops because the underlying liver disease still poses a risk.
How often will I need scans after HCC treatment?
For the first two years, you will typically need high-intensity monitoring with an MRI or CT scan and an AFP blood test every three to six months. The frequency usually decreases to every six to twelve months after year five.
What is scanxiety and how can I manage it?
Scanxiety is the spike of distress patients feel around the time of follow-up imaging appointments. Managing it involves understanding the physical sensations of the scan and asking your doctor to release results through a patient portal as soon as they are ready to minimize wait times.
What can I do to lower my risk of late HCC recurrence?
Proactively managing your underlying liver health can lower your risk. This includes treating conditions like Hepatitis C, controlling diabetes, maintaining a healthy weight, and exercising regularly.
What complications should caregivers watch for after HCC treatment?
Caregivers should monitor for signs of liver decompensation or hepatic encephalopathy. Confusion or subtle behavioral changes can be early warning signs that the remaining liver is struggling to function properly and should be reported to your medical team.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is my specific surveillance schedule for the next two years, and which imaging (MRI or CT) will we use?
  2. 2.Does my pathology report put me at a higher risk for 'early recurrence'?
  3. 3.Since late recurrence is linked to my underlying liver health, what can we do to manage my cirrhosis or fatty liver disease now?
  4. 4.If I had a transplant, how often will we check my immunosuppressant levels, and how do these levels affect my cancer risk?
  5. 5.Who should I contact if I notice new symptoms, like pain or weight loss, between my scheduled scans?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Impact of compliance to postoperative regular follow-up on long-term prognosis after curative resection for hepatocellular carcinoma: A multicenter analysis.

    Yao LQ, Gong JB, Cai L, et al.

    Hepatobiliary & pancreatic diseases international : HBPD INT 2025; (24(3)):261-268 doi:10.1016/j.hbpd.2025.03.003.

    PMID: 40148147
  2. 2

    Predictors of early and late hepatocellular carcinoma recurrence.

    Nevola R, Ruocco R, Criscuolo L, et al.

    World journal of gastroenterology 2023; (29(8)):1243-1260 doi:10.3748/wjg.v29.i8.1243.

    PMID: 36925456
  3. 3

    Predictors and long-term prognosis of early and late recurrence for patients undergoing hepatic resection of hepatocellular carcinoma: a large-scale multicenter study.

    Yan WT, Li C, Yao LQ, et al.

    Hepatobiliary surgery and nutrition 2023; (12(2)):155-168 doi:10.21037/hbsn-21-288.

    PMID: 37124678
  4. 4

    Risk Factors, Patterns, and Outcomes of Late Recurrence After Liver Resection for Hepatocellular Carcinoma: A Multicenter Study From China.

    Xu XF, Xing H, Han J, et al.

    JAMA surgery 2019; (154(3)):209-217 doi:10.1001/jamasurg.2018.4334.

    PMID: 30422241
  5. 5

    Early Versus Late Recurrence of Hepatocellular Carcinoma After Surgical Resection Based on Post-recurrence Survival: an International Multi-institutional Analysis.

    Wei T, Zhang XF, Bagante F, et al.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2021; (25(1)):125-133 doi:10.1007/s11605-020-04553-2.

    PMID: 32128681
  6. 6

    Surgical Treatment of Hepatocellular Carcinoma Arising from Fontan-associated Liver Disease: A Report of Three Cases.

    Rinka K, Kioka K, Amano Y, et al.

    Internal medicine (Tokyo, Japan) 2025; (64(12)):1834-1842 doi:10.2169/internalmedicine.4631-24.

    PMID: 39603624
  7. 7

    Clinical outcomes of patients with a high alpha-fetoprotein level but without evident recurrence on CT or MRI in surveillance after curative-intent treatment for hepatocellular carcinoma.

    Lee J, Joo I, Lee DH, et al.

    Abdominal radiology (New York) 2021; (46(2)):597-606 doi:10.1007/s00261-020-02707-z.

    PMID: 32812065
  8. 8

    Application and progress of the detection technologies in hepatocellular carcinoma.

    Yan Q, Sun YS, An R, et al.

    Genes & diseases 2023; (10(5)):1857-1869 doi:10.1016/j.gendis.2022.04.003.

    PMID: 37492708
  9. 9

    Recurrence beyond the Milan criteria after curative-intent resection of hepatocellular carcinoma: A novel tumor-burden based prediction model.

    Tsilimigras DI, Mehta R, Guglielmi A, et al.

    Journal of surgical oncology 2020; (122(5)):955-963 doi:10.1002/jso.26091.

    PMID: 32602143
  10. 10

    Development and Validation of an Individualized Prediction Model for Postoperative Late Recurrence After Hepatectomy for Hepatocellular Carcinoma (POLAR-HCC): A Multicenter Study.

    Xu XF, Wu H, Gu LH, et al.

    Annals of surgical oncology 2025; (32(13)):9573-9583 doi:10.1245/s10434-025-18213-9.

    PMID: 40928575
  11. 11

    Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

    Derry-Vick HM, Heathcote LC, Glesby N, et al.

    Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

    PMID: 36900174
  12. 12

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  13. 13

    The experience of patients participating in a small randomised control trial that explored two different interventions to reduce anxiety prior to an MRI scan.

    Tugwell-Allsup J, Pritchard AW

    Radiography (London, England : 1995) 2018; (24(2)):130-136 doi:10.1016/j.radi.2017.11.001.

    PMID: 29605109
  14. 14

    Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

    Dunsmore VJ, Neupert SD

    Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

    PMID: 36964680
  15. 15

    Albumin-Bilirubin Score vs Model for End-Stage Liver Disease in Predicting Post-Hepatectomy Outcomes.

    Fagenson AM, Gleeson EM, Pitt HA, Lau KN

    Journal of the American College of Surgeons 2020; (230(4)):637-645 doi:10.1016/j.jamcollsurg.2019.12.007.

    PMID: 31954813
  16. 16

    Circulating exosomal miR-92b: Its role for cancer immunoediting and clinical value for prediction of posttransplant hepatocellular carcinoma recurrence.

    Nakano T, Chen IH, Wang CC, et al.

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2019; (19(12)):3250-3262 doi:10.1111/ajt.15490.

    PMID: 31162867
  17. 17

    Distinct patterns of late recurrence in long-term hepatocellular carcinoma survivors.

    Akabane M, Kawashima J, Woldesenbet S, et al.

    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract 2025; (29(9)):102135 doi:10.1016/j.gassur.2025.102135.

    PMID: 40578426
  18. 18

    Systematic Review of Studies Assessing the Health-Related Quality of Life of Hepatocellular Carcinoma Patients from 2009 to 2018.

    Kang D, Shim S, Cho J, Lim HK

    Korean journal of radiology 2020; (21(6)):633-646 doi:10.3348/kjr.2019.0808.

    PMID: 32410403
  19. 19

    Health-related quality of life in Thai patients with hepatocellular carcinoma and its influencing factors: A cross-sectional study.

    Pathomjaruwat T, Matchim Y, Armer JM

    Belitung nursing journal 2025; (11(4)):370-383 doi:10.33546/bnj.3853.

    PMID: 40766262

This page provides general surveillance and survivorship guidelines for HCC for educational purposes only. Always consult your oncology team for your specific follow-up schedule and personal recurrence risks.

Get notified when new evidence is published on Adult hepatocellular carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.